Acute myeloid leukemia
Conditions
Interventions
Group A:HIA scheme
Group B:HAD scheme
Sponsors
Shanxi Bethune Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with aged 18 to 60 years old male and female; 2. Patients with FLT3 / ITD + acute myeloid leukemia diagnosed by morphology, immunology and genetics of bone marrow cells were diagnosed according to the World Health Organization (who) diagnostic criteria, including patients with newly diagnosed and relapsed FLT3 / ITD + acute myeloid leukemia; 3. Patients who meet the diagnostic criteria for refractory AML (2011 Chinese guidelines for diagnosis and treatment of relapsed and refractory acute myeloid leukemia) (1) The patients who did not get complete remission after 2 courses of standard induction chemotherapy; (2) Patients who relapsed within 6 months after the first complete remission; (3) The patients who relapsed 6 months after the first complete remission were failed in the induction chemotherapy; (4) Patients with two or more relapses; (5) Patients with persistent extramedullary leukemia; 4. Patients meeting the diagnostic criteria of recurrent AML (refer to NCCN guidelines in 2014): after complete remission, peripheral blood cells appeared; bone marrow immature cells > 5%; extramedullary recurrence; 5. Choose HIA or had regimen according to patient's condition, medication history and economic condition; 6. Patients with ECOG-ps score of 0-2 in Eastern oncology collaboration group.
Exclusion criteria
Exclusion criteria: 1. Patients with cerebral hemorrhage; 2. The object of pregnancy; 3. Patients with mental illness or other conditions that cannot be carried out according to the plan; 4. Patients with severe arrhythmia and abnormal ECG (QT > 500ms); 5. Patients who do not sign informed consent form; 6. Other situations that the researcher thinks are not suitable for the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate;Relapse Rate;Event free survival;Overall survival;Peripheral blood primitive cell count in agranulocytosis; | — |
Countries
China
Contacts
Public ContactTao Wang
Shanxi Bethune Hospital Affiliated to Shanxi Medical University
Outcome results
None listed